Products
Moxetumomab Pasudotox Biosimilar Fusion Protein (CD22) for Research
Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-920-1mg | 1mg | 3090 |
| GMP-Bios-INN-920-10mg | 10mg | |
| GMP-Bios-INN-920-100mg | 100mg | |
| GMP-Bios-INN-920-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A |
| INN Name | Moxetumomab Pasudotox |
| Target | CD22 |
| Format | Fusion Protein |
| Derivation | Mus musculus |
| Species Reactivity | human |
| CH1 Isotype | Fv - disulfide stabilized |
| VD LC | Fv - disulfide stabilized |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | MedImmune (Gaithersburg MD USA) / AstraZeneca (London UK) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | Cambridge Antibody Technology (CAT) human antibody phage display library |
About target - CD22
1. Protein B-cell receptor CD22
2. Gene CD22
3. Organism Homo sapiens (Human)
Function
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa.
Miscellaneous
In 1952, one of the earliest researchers of the disease, Dr. R.G. Macfarlane used the patient's surname, Christmas, to refer to the disease and also to refer to the clotting factor which he called the 'Christmas Factor' At the time Stephen Christmas was a 5-year-old boy. He died in 1993 at the age of 46 from acquired immunodeficiency syndrome contracted through treatment with blood products.
Catalytic activity
Selective cleavage of Arg-|-Ile bond in factor X to form factor Xa.
